Speciality Medicines Limited
Bookbuilding IPO · BSE
- Price band
- ₹117 - ₹124
- Lot size
- 1,000 shares
- Issue amount
- ₹29.14 cr
- Total subscription
- 2.33×
- Opens
- 20 Mar 2026
- Closes
- 24 Mar 2026
- Allotment
- 25 Mar 2026
- Listing
- 30 Mar 2026
Offer at a glance
Issue overview
- Issue size
- 23,50,000 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,17,000
- Fresh issue
- ₹29.14 cr
- Offer for sale
- ₹0 cr
- Registrar
- Skyline Financial Services Private Limited
- Listing exchange
- BSE
- Maximum investment
- ₹1,24,000
- Issue type
- Bookbuilding IPO
- Shares before issue
- 64,35,796
- Shares after issue
- 87,85,796
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 2 | 2,000 | ₹2,48,000 |
| sHNI | 3 | 3,000 | ₹3,72,000 |
| bHNI | 9 | 9,000 | ₹11,16,000 |
Share reservation
Subscription & GMP
Subscription by category
Reported 24 Mar 2026
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| QIB | 0 | 2 |
| NIB | 0 | 222 |
| RETAIL | 545 | 461 |
| HNIs(10L +) | 242 | 167 |
| HNIs (2-10L) | 121 | 55 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 0.26 | 25.06 |
| FIIs | 0 | 25.06 |
| RETAIL | 13.52 | 11.43 |
| NIB | 13.5 | 27.21 |
| HNIs 2+ | 4.5 | 2.86 |
| HNIs 10+ | 9 | 24.34 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Oct-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| EPS | 9.41 | 14.1 | 7.07 | 4.74 |
| ROE | 0 | 0 | 0 | 0 |
| ROCE | 16.86 | 33.39 | 36.9 | 50.22 |
| RONW | 16.61 | 28.3 | 19.47 | 28.6 |
| PRE IPO(PE) | 0 | 9.27 | 0 | 0 |
| POST IPO(PE) | 10.49 | 0 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Speciality Medicines Limited | 9.27 | 0 | 10.00 | 47.26 | 28.42 | 14.10 |
| Remus Pharmaceuticals Limited | 10.41 | 0 | 10.00 | 434.25 | 15.02 | 65.21 |
| Trident Lifeline Limited | 27.00 | 0 | 10.00 | 56.05 | 18.23 | 10.22 |
| Mono Pharmacare Limited | 7.49 | 0 | 10.00 | 17.66 | 9.90 | 1.75 |
Company information
Company profile
Speciality Medicines Limited was incorporated in 2021 and focuses on marketing and distributing speciality pharmaceutical medicines, including expensive oral and injectable drugs used to treat serious and long-term health conditions in both Indian and international markets. The company offers many types of finished pharmaceutical products in different forms such as tablets, capsules, creams, syrups, eye drops, gels, injections, inhalers, nasal sprays, ointments, sachets, and suspensions. It operates through two main models: contract manufacturing of finished medicines for international markets and marketing and distribution of speciality medicines sourced from other manufacturers. The company has expanded globally with products registered or under registration in countries like Jordan, Ethiopia, Uganda, Peru, and Namibia, and its distribution network covers more than 20 states in India and over 35 countries worldwide. As of March 31, 2025, one product was registered overseas and 60 products were under registration in five countries, contributing to revenue, and as of August 31, 2025, the company had 18 permanent employees working in different departments.
Strengths
- Wide Global Presence: The company operates in India as well as several international markets, helping it build a diversified revenue base and reduce dependence on a single region.
- Strong Customer Relationships: By focusing on customer needs, timely delivery, and consistent product quality, the company has developed long-term relationships and receives repeat orders from its clients.
- Reliable Quality Standards: The company follows strict quality control practices supported by ISO 9001:2015 certification and trusted third-party manufacturing facilities, ensuring consistent product quality and on-time delivery.
Risk factors
- Dependence on Third-Party Suppliers: The company relies on external suppliers for sourcing products. Any disruption, delay, or price fluctuations from these suppliers may affect product availability, pricing, and overall operations.
- Strict Quality Compliance Requirements: The company’s products must meet specific customer specifications and quality standards. Any failure to meet these requirements may result in product recalls, order cancellations, or warranty claims.
- Limited In-House R&D Capability: The company currently does not have a well-established in-house R&D team. Delays in developing this capability may impact product innovation and future growth opportunities.
Promoters
Parth B Goyani
Goyani Sumit Babubhai
Registrar & documents
Lead manager
Unicon Capital Services Private Limited
Registrar & contacts
Skyline Financial Services Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
913, One World West, S. No. 396, FP 119, Village- Vejalpur, Ahmadabad City, Ahmedabad, Gujarat, India, Ahmedabad, Gujarat, 380051
+91 22 4604 5344
[email protected]Company website ↗Understanding SPML IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.